Allogene Therapeutics, Inc.
ALLO · NASDAQ
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 12, 2026 | — | 2.22K | — | -0.16 | — |
| 2026 Q1 | May 13, 2026 | — | 2.22K | -0.18 | -0.19 | -8.15% |
| 2025 Q4 | March 12, 2026 | — | 2.50K | -0.17 | -0.25 | -2.83% |
| 2025 Q3 | November 6, 2025 | — | 1.82K | -0.19 | -0.23 | +12.38% |
| 2025 Q2 | August 13, 2025 | — | — | -0.23 | -0.28 | +2.88% |
| 2025 Q1 | May 13, 2025 | — | 1.67K | -0.28 | -0.28 | -15.68% |
| 2024 Q4 | March 13, 2025 | 22.00K | 12.00K | -0.28 | -0.34 | +2.65% |
| 2024 Q3 | November 7, 2024 | — | 12.11K | -0.27 | -0.34 | -3.45% |
| 2024 Q2 | August 7, 2024 | — | 20.00K | -0.32 | -0.35 | -4.45% |
| 2024 Q1 | May 13, 2024 | 22.00K | 10.00K | -0.38 | -0.38 | +2.07% |
| 2023 Q4 | March 14, 2024 | 21.00K | 20.00K | -0.43 | -0.47 | +3.67% |
| 2023 Q3 | November 2, 2023 | 43.00K | 20.00K | -0.37 | -0.53 | +17.85% |
| 2023 Q2 | August 2, 2023 | 44.00K | 20.00K | -0.53 | -0.59 | +9.59% |
| 2023 Q1 | May 3, 2023 | 52.00K | 10.00K | -0.68 | -0.63 | +12.76% |
| 2022 Q4 | February 28, 2023 | 47.00K | 77.18K | -0.66 | -0.71 | -0.16% |
| 2022 Q3 | November 2, 2022 | 49.00K | 7.17K | -0.58 | -0.62 | -6.39% |